Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Enara Bio Limited is currently overseeing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter involves 1 distinct examiner and is situated within 1 distinct art unit. Such a structure shows that the company's patent office interactions are currently limited to a specific technical field. The use of a single art unit implies that the subject matter of the application is categorized under a particular regulatory framework at the patent office.
The busiest examiner for the company is VAN DRUFF, SYDNEY, who is currently processing 1 pending office action. Because this examiner is the only one assigned to the company's pending workload, they serve as the primary point of contact for all current prosecution efforts. For a practitioner, the success of the application relies on addressing the specific concerns raised by this examiner. The absence of other pending matters means there are no conflicting examiner requirements to balance. This streamlined prosecution environment allows for a highly targeted approach to resolving the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17644938 | NOVEL CANCER ANTIGENS AND METHODS | VAN DRUFF, SYDNEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17644938 | NOVEL CANCER ANTIGENS AND METHODS | VAN DRUFF, SYDNEY | 1643 | §103§112DP | Non-Final OA | — | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial